Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Nephrology

Validation and Orientation: Understanding Calciphylaxis

At a Glance

Calciphylaxis is a rare, serious condition in which calcium builds up in small blood vessels in the skin and fat, reducing blood flow and causing severe pain and wounds. Early, coordinated care focuses on pain, mineral balance, wound protection, and infection control.

Receiving a diagnosis of calciphylaxis can feel overwhelming and frightening. It is a rare condition that most people have never heard of, yet it causes an intensity of pain that is difficult to describe to others. If you are feeling scared or if your pain feels “off the charts,” know that your experience is a recognized hallmark of this disease [1][2].

This page will help you understand what is happening inside your body, why it is so painful, and what a diagnosis means.

What is Calciphylaxis?

Calciphylaxis (also called calcific uremic arteriolopathy) is a serious condition where calcium builds up in the walls of the small blood vessels in your skin and fat [3]. This buildup causes the vessels to narrow and eventually develop small blood clots (thrombosis), which block the flow of oxygen-rich blood to your tissues [4][5].

When the blood supply is cut off, the tissue begins to die—a process called necrosis. This usually starts as firm, purple, or red patches on the skin that may eventually turn into deep, non-healing wounds [6][7].

Why It Happens

While the exact cause is still being studied, doctors know it is a complex process involving several factors [3]:

  • Mineral Imbalance: It most commonly affects people with advanced kidney disease or those on dialysis (though “non-uremic” cases can rarely occur without kidney disease), where the body struggles to balance calcium and phosphate [3][8].
  • Vessel Changes: The smooth muscle cells in your blood vessels may “transform” into bone-like cells, making the vessels stiff and prone to blockage [9].
  • Loss of Inhibitors: Your body normally has proteins that prevent calcium from sticking to vessel walls; in calciphylaxis, these “brakes” may stop working [9].

Validating Your Pain

One of the most distressing parts of calciphylaxis is the pain. Studies show that roughly 74% of patients report severe pain at the time of diagnosis, often rating it an 8 out of 10 or higher [1].

This pain is not an exaggeration; it is a direct result of the biological process:

  • Ischemia: Because the blood vessels are blocked, your nerves and tissues are “suffocating” from a lack of oxygen (ischemia). This can cause a deep, agonizing, or burning sensation even before a visible wound appears [10][11].
  • Inflammation: As the tissue is damaged, the body’s inflammatory response adds to the sensitivity and swelling in the area [12].
  • Clotting: The presence of tiny blood clots in the skin has been specifically linked to higher levels of pain [1].

Understanding the Rarity

Calciphylaxis is considered a rare disease. While it is most common in patients on hemodialysis (where some historical estimates suggest it may affect around 3.5 per 1,000 patient-years), it is much rarer in the general population [13][14]. Because it is so uncommon, it is vital to be cared for by a multidisciplinary team of specialists who are familiar with the latest research [6][15].

Facing the Prognosis

Being honest about the outlook for calciphylaxis is difficult because historical population statistics can be sobering. In older observational studies, the reported one-year mortality rate ranged widely from 31% to 80%, largely depending on whether the skin had developed open ulcers and the patient’s overall health [16][17].

However, it is crucial to understand that population statistics do not predict your individual outcome. Your risks depend heavily on your specific comorbidities, the extent of your wounds, and how quickly infection can be managed. There are several reasons for active engagement in your care:

  • Earlier Intervention: Catching the disease early allows for prompt evaluation and medical management before severe wounds open [18][19].
  • Advanced Wound Care: Modern techniques in wound management and infection control are helping patients manage the disease more effectively and fight off sepsis [6][20].
  • Multidisciplinary Care: When specialists work together to manage your dialysis, nutrition, and medications, they can often improve your quality of life and help control the progression [6][21].

Your medical team’s primary goal is to manage your pain, treat the underlying mineral imbalances, and protect your skin. While the path ahead is challenging, you are not alone, and your symptoms are being taken seriously.

Common questions in this guide

Why is calciphylaxis pain often so severe?
Calciphylaxis narrows or blocks tiny blood vessels in the skin and fatty tissue, reducing oxygen delivery and causing pain. Inflammation and small clots can add to the deep, burning pain, which may start before an open wound appears.
What does calciphylaxis look like on the skin?
It may begin as firm red or purple patches that are very painful or sensitive. As blood flow worsens, the affected tissue can die and develop deep, non-healing wounds.
Who is most likely to develop calciphylaxis?
Calciphylaxis most often affects people with advanced kidney disease, especially those receiving hemodialysis, because calcium and phosphate can become difficult to balance. Rare non-uremic cases can also occur in people without kidney disease.
How is calciphylaxis different from a severe skin infection?
Calciphylaxis and severe skin infections can cause overlapping skin changes, so a clinician must assess the full picture rather than rely on one symptom. Ask your care team how certain the diagnosis is and whether nephrology, dermatology, and wound-care specialists should be involved.
What treatments are used to manage calciphylaxis?
Care focuses on controlling severe pain, correcting calcium and phosphate imbalances, protecting the skin, and treating or preventing infection. Wound care, dialysis and nutrition management, and medication review may be coordinated by a multidisciplinary team.
What is the outlook for someone with calciphylaxis?
Published population statistics report a wide range of one-year mortality, but those numbers cannot predict an individual person's outcome. Prognosis depends on factors such as open wounds, other health conditions, infection control, and how quickly care begins; early, coordinated care can support disease management and quality of life.

Get notified when new evidence is published on Calciphylaxis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Correlation between clinical and pathological features of cutaneous calciphylaxis.

    Dutta P, Chaudet KM, Nazarian RM, et al.

    PloS one 2019; (14(6)):e0218155 doi:10.1371/journal.pone.0218155.

    PMID: 31194797
  2. 2

    Calciphylaxis Penile Lesion: An Unusual Complication of End-Stage Renal Disease.

    Grote J, Geyer-Roberts E, Banuelos A, et al.

    Cureus 2025; (17(3)):e80625 doi:10.7759/cureus.80625.

    PMID: 40230779
  3. 3

    Calciphylaxis diagnosis, management and future directions: a comprehensive update on behalf of the European Renal Association CKD-MBD Working Group.

    Huish S, Moore S, Alfieri C, et al.

    Clinical kidney journal 2025; (18(12)):sfaf338 doi:10.1093/ckj/sfaf338.

    PMID: 41367922
  4. 4

    Diagnosing Calciphylaxis: A Review With Emphasis on Histopathology.

    Bahrani E, Perkins IU, North JP

    The American Journal of dermatopathology 2020; (42(7)):471-480 doi:10.1097/DAD.0000000000001526.

    PMID: 32604207
  5. 5

    Isolated Mesenteric Calciphylaxis With Ischemic Colitis in a Hemodialysis Patient Without Active Cutaneous Calciphylaxis: A Case Report of Calcific Uremic Arteriolopathy.

    Tan RYP, Juneja R, Gunawardane DN, Milton CA

    Kidney medicine 2020; (2(2)):209-212 doi:10.1016/j.xkme.2019.12.005.

    PMID: 32734240
  6. 6

    An Update on Calciphylaxis.

    García-Lozano JA, Ocampo-Candiani J, Martínez-Cabriales SA, Garza-Rodríguez V

    American journal of clinical dermatology 2018; (19(4)):599-608 doi:10.1007/s40257-018-0361-x.

    PMID: 29808451
  7. 7

    Histopathology of Calciphylaxis: Cohort Study With Clinical Correlations.

    Chen TY, Lehman JS, Gibson LE, et al.

    The American Journal of dermatopathology 2017; (39(11)):795-802 doi:10.1097/DAD.0000000000000824.

    PMID: 29053546
  8. 8

    Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry.

    Brandenburg VM, Kramann R, Rothe H, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(1)):126-132 doi:10.1093/ndt/gfv438.

    PMID: 26908770
  9. 9

    Calciphylaxis: ongoing challenges and treatment opportunities with mesenchymal stem cells.

    Wu D, Lu S, Hu J, et al.

    Journal of molecular cell biology 2025; (17(2)) doi:10.1093/jmcb/mjaf009.

    PMID: 40097288
  10. 10

    Calciphylaxis: from the disease to the diseased.

    Oliveira TM, Frazão JM

    Journal of nephrology 2015; (28(5)):531-40 doi:10.1007/s40620-015-0192-2.

    PMID: 25835730
  11. 11

    Penile Calciphylaxis: A Successfully Treated Case.

    Misakyan N, Abu-Shanab A, Shah S

    Cureus 2024; (16(2)):e54824 doi:10.7759/cureus.54824.

    PMID: 38529436
  12. 12

    Calciphylaxis: A Rare Manifestation of a Common Disease.

    Nancassa C, Baiherych T, Figueiredo A

    Cureus 2025; (17(5)):e84550 doi:10.7759/cureus.84550.

    PMID: 40546520
  13. 13

    Calciphylaxis.

    Nigwekar SU

    Current opinion in nephrology and hypertension 2017; (26(4)):276-281 doi:10.1097/MNH.0000000000000328.

    PMID: 28375870
  14. 14

    A Case Report of Non-Uremic Calciphylaxis Refractory to Treatment Requiring Multidisciplinary Care.

    Lee R, Kahn H, Aiad M, Wilson M

    Case reports in dermatology 2025; (17(1)):471-477 doi:10.1159/000547832.

    PMID: 41059361
  15. 15

    Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?

    Brandenburg VM, Evenepoel P, Floege J, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(8)):1211-9 doi:10.1093/ndt/gfw025.

    PMID: 27005994
  16. 16

    Assessment of diagnostic delay, morbidity, and mortality outcomes in 302 calciphylaxis patients over a 17-year period: A retrospective cohort study.

    Tan AJ, Xia J, Glennon CM, et al.

    Journal of the American Academy of Dermatology 2024; (91(5)):834-842 doi:10.1016/j.jaad.2024.06.058.

    PMID: 38972479
  17. 17

    Calcific Uremic Arteriolopathy in End-Stage Renal Disease: A Rare Life-Threatening Condition.

    Okan T, Ghuman K, Chaudhary F, et al.

    Cureus 2023; (15(10)):e48002 doi:10.7759/cureus.48002.

    PMID: 38034199
  18. 18

    Clinical features and outcomes of calciphylaxis in Chinese patients with chronic kidney disease.

    Jiao Y, Sun L, Xie X, et al.

    Nephrology (Carlton, Vic.) 2023; (28(6)):305-314 doi:10.1111/nep.14156.

    PMID: 36883928
  19. 19

    Clinical mimickers of calciphylaxis: A retrospective study.

    Gabel CK, Blum AE, François J, et al.

    Journal of the American Academy of Dermatology 2021; (85(6)):1520-1527 doi:10.1016/j.jaad.2021.03.035.

    PMID: 33744358
  20. 20

    Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study.

    Gaisne R, Péré M, Menoyo V, et al.

    BMC nephrology 2020; (21(1)):63 doi:10.1186/s12882-020-01722-y.

    PMID: 32101140
  21. 21

    Ten tips on how to deal with calciphylaxis patients.

    Chewcharat A, Nigwekar SU

    Clinical kidney journal 2025; (18(4)):sfaf098 doi:10.1093/ckj/sfaf098.

    PMID: 40600068

This page is for informational purposes only and does not constitute medical advice about calciphylaxis. Your nephrology, dermatology, and wound-care team should evaluate your symptoms and guide your treatment.

Guide contents Calciphylaxis
Research & Literature
02 Symptoms, Warning Signs, and Emergencies